FAU own research funding: EFI / IZKF / EAM ...
Start date : 01.09.2020
End date : 31.08.2021
Extension date: 31.07.2024
Clinical and animal studies implicate neuroinflammatory features (interleukines, chemokines, adipokines, oxytocin, alarmins) as part of the pathophysiology. BurstDR-SCS and DRG-SCS stimulation present a paradigm shift in current neurostimulation to address the treatment of CPSP-associated pain. Such molecular analysis may underpin the emerging role of CPSP-related molecular patterns as potential biomarkers to reliably reproduce spinal stimulation effects.